Pediatric Long-Term Follow-up and Rollover Study

IsraelRecruitingPHASE4

Conditions

Diffuse Astrocytoma · Anaplastic Astrocytoma · Astrocytoma · Oligodendroglioma, Childhood · Anaplastic Oligodendroglioma · Glioblastoma · Pilocytic Astrocytoma · Giant Cell Astrocytoma · Pleomorphic Xanthoastrocytoma · Anaplastic Pleomorphic Xanthoastrocytoma · Angiocentric Glioma · Chordoid Glioma of Third Ventricle · Gangliocytoma · Ganglioglioma · Anaplastic Ganglioglioma · Dysplastic Gangliocytoma of Cerebrellum · Desmoplastic Infantile Astrocytoma and Ganglioglioma · Papillary Glioneuronal Tumor · Rosette-forming Glioneuronal Tumor · Central Neurocytoma · Extraventricular Neurocytoma · Cerebellar Liponeurocytoma · Neurofibromatosis Type 1

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Phoenix Children s Hospital, Phoenix, Arizona, United States

  • Childrens National Hospital, Washington D.C., District of Columbia, United States

  • Nicklaus Childrens Hospital, Miami, Florida, United States

  • Indiana Uni School of Medicine, Indianapolis, Indiana, United States

  • Johns Hopkins Hospital, Baltimore, Maryland, United States

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

  • University of Minnesota, Minneapolis, Minnesota, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Jessica Sollitto) · dunkel@MSKCC.ORG · 212-639-3112
    Contact: Principal Investigator (Stephen Gilheeney)
  • Memorial Sloan Kettering Cancer Ctr, New York, New York, United States

  • Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States

  • St Jude Childrens Research Hospital, Memphis, Tennessee, United States

  • Texas Childrens Hospital, Houston, Texas, United States

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site, Parkville, Victoria, Australia

  • Novartis Investigative Site, Brussels, Belgium

  • Novartis Investigative Site, Barretos, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Vancouver, British Columbia, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Brno, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Copenhagen, Denmark

  • Novartis Investigative Site, Tampere, Finland

  • Novartis Investigative Site, Rennes, Brittany Region, France

  • Novartis Investigative Site, Brest, France

  • Novartis Investigative Site, Marseille, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Vandœuvre-lès-Nancy, France

  • Novartis Investigative Site, Villejuif, France

  • Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Augsburg, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Florence, FI, Italy

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Torino, TO, Italy

  • Novartis Investigative Site, Setagaya-ku, Tokyo, Japan

  • Novartis Investigative Site, Osaka, Japan

  • Novartis Investigative Site, Utrecht, Netherlands

  • Novartis Investigative Site, Moscow, Russia

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Stockholm, Sweden

  • Novartis Investigative Site, Sutton, Surrey, United Kingdom

  • Novartis Investigative Site, Liverpool, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

Study leads
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals